These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32103106)

  • 1. High WBP5 expression correlates with elevation of HOX genes levels and is associated with inferior survival in patients with acute myeloid leukaemia.
    Ward C; Cauchy P; Garcia P; Frampton J; Esteban MA; Volpe G
    Sci Rep; 2020 Feb; 10(1):3505. PubMed ID: 32103106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.
    Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
    [No Abstract]   [Full Text] [Related]  

  • 4. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
    Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
    Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
    Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.
    Rozovskaia T; Feinstein E; Mor O; Foa R; Blechman J; Nakamura T; Croce CM; Cimino G; Canaani E
    Oncogene; 2001 Feb; 20(7):874-8. PubMed ID: 11314021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
    Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
    Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
    Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
    Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.
    Arabanian LS; Johansson P; Staffas A; Nilsson T; Rouhi A; Fogelstrand L; Palmqvist L
    Leuk Res; 2018 Dec; 75():61-68. PubMed ID: 30384975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome Profiling of Pediatric Core Binding Factor AML.
    Hsu CH; Nguyen C; Yan C; Ries RE; Chen QR; Hu Y; Ostronoff F; Stirewalt DL; Komatsoulis G; Levy S; Meerzaman D; Meshinchi S
    PLoS One; 2015; 10(9):e0138782. PubMed ID: 26397705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.
    Calvo KR; Sykes DB; Pasillas MP; Kamps MP
    Oncogene; 2002 Jun; 21(27):4247-56. PubMed ID: 12082612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
    Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
    Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Wang W; Li H; Huang M; Wang X; Li W; Qian X; Jing L
    Open Biol; 2022 Oct; 12(10):220172. PubMed ID: 36285442
    [No Abstract]   [Full Text] [Related]  

  • 15. MEIS1 and HOXA7 genes in human acute myeloid leukemia.
    Afonja O; Smith JE; Cheng DM; Goldenberg AS; Amorosi E; Shimamoto T; Nakamura S; Ohyashiki K; Ohyashiki J; Toyama K; Takeshita K
    Leuk Res; 2000 Oct; 24(10):849-55. PubMed ID: 10996203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
    Zidan MA; Kamal Shaaban HM; Elghannam DM
    Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature.
    Volpe G; Walton DS; Grainger DE; Ward C; Cauchy P; Blakemore D; Coleman DJL; Cockerill PN; Garcia P; Frampton J
    Sci Rep; 2017 Sep; 7(1):11148. PubMed ID: 28894287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia.
    Zhu GZ; Yang YL; Zhang YJ; Liu W; Li MP; Zeng WJ; Zhao XL; Chen XP
    Cell Physiol Biochem; 2017; 42(5):1973-1984. PubMed ID: 28793301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.